Showing 109–120 of 192 resultsSorted by latest
Pharma & Biotech
United Therapeutics (UTHR) is a biotechnology company focused on developing and commercializing innovative therapies for patients with serious diseases, particularly pulmonary arterial hypertension (PAH) and cancer.
In the third quarter of 2024, Gilead’s total product sales increased by 7% to $7.5 billion compared to the same period in 2023.
MRK is launching important new products that address unmet medical needs and have significant commercial potential.
In Q3, Thermo Fisher’s pharma and biotech segment declined slightly, down in the low single digits, mainly due to the decrease in vaccine and therapy revenue.
LEQEMBI’s revenue in the U.S. is still below Biogen’s expectations, and the prescriber base hasn’t grown as much as anticipated.
Abbott achieved several key milestones in its biosimilars portfolio, with the first biosimilar set to launch in emerging markets by late 2025
Johnson & Johnson has recently acquired Shockwave and V-Wave in MedTech, along with Ambrx, Proteologix, and NM26 in Innovative Medicine.
ADMA is a commercial biopharmaceutical company focused on manufacturing, marketing, and developing speciality biologics to treat immunodeficient patients and others at risk for infections.
In the quarter, Royalty Pharma acquired royalties on six therapies, including one approved therapy and five in development.
MDT is at a pivotal moment in med-tech with its new PFA technology for AFib, which is rapidly changing disease treatment.
In May 2024, AstraZeneca completed a $140 million equity investment in Cellectis, a biotech company focused on gene editing.
Gilead recently reported positive results from the Phase 3 PURPOSE 1 trial of lenacapavir for HIV prevention, showing 100% efficacy with no infections in cisgender women